Importantly, using genetically engineered mice, selective deletion of Nhe1 from Cx3cr1+ microglia/myeloid cells elevated CD4+PD-1+ and CD8+PD-1+ tumor infiltration in response to TMZ monotherapy. The gene discussed is CD8A; the disease is neoplasm.